Drug intelligence / Profile preview

AK0706

Development stage: Phase 1
Lead developer: Xiamen Tebao Biological Engineering
Modality: Recombinant Proteins and Enzymes
Administration: Injection

Overview

AK0706 is an investigational recombinant protein therapeutic developed by Xiamen Amoytop (Xiamen Amoytop Biotech) for the treatment of chronic hepatitis B. Positioned within the company's immunology pipeline, AK0706 is designed to address the clinical needs of patients with hepatitis B, potentially through immune modulation or direct antiviral activity. The drug is currently in Phase 1 clinical development, where its safety, tolerability, and pharmacokinetic profile are being evaluated in human subjects.

Targets

IL2RA (Interleukin-2 receptor alpha subunit)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)

Beyond the preview

Go deeper on AK0706.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK0706.